Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    LIPAD
Previous Study | Return to List | Next Study

LIPAD - LRRK2 International Parkinson's Disease Study (LIPAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04214509
Recruitment Status : Recruiting
First Posted : January 2, 2020
Last Update Posted : February 27, 2020
Sponsor:
Collaborator:
CENTOGENE GmbH Rostock
Information provided by (Responsible Party):
Meike Kasten, University of Luebeck

Brief Summary:
The study aims to identify and systematically characterize Parkinson's patients with mutations in the LRRK2 gene. In about 90% of Parkinson's patients the cause of the disease is unclear. Based on current knowledge, it can be assumed that there are several causes and that the causes may be differ between patients; this makes research into the pathogenesis and possible therapies very difficult. In the case of monogenic Parkinson's diseases, which are due to changes in one gene (e.g. LRRK2), the function of the gene and possible disease mechanisms can be investigated. LRRK2-associated Parkinson's syndrome is clinically indistinguishable from idiopathic Parkinson's disease. It is inherited autosomal dominant, that means if one of the two gene copies is altered, the disease occurs. However, the disease does not occur in every mutation carrier, the penetrance is reduced and the mechanisms for that are still unclear. Ideally, knowledge of what influences penetrance could make it possible to exert targeted influence and prevent the disease. The comprehensive investigation of mechanisms of reduced penetrance but also of the effects of the mutation itself requires systematic investigations of as many affected persons as possible. We therefore aim to identify 4,000 people internationally, of them 1,500 with LRRK2-associated Parkinson's syndrome, 500 with LRRK2-mutations but without Parkinson's symptoms, 500 without mutations and without Parkinson's symptoms, 500 Parkinson patients with mutations in other genes than LRRK2 and 1,000 patients with idiopathic Parkinson's disease from the same populations. The participants will undergo a comprehensive survey on Parkinson's symptoms, concomitant diseases, environmental factors and medication and there is the possibility of more detailed genetic examinations. Participants will be asked to donate samples of blood, urine and household dust.

Condition or disease
Parkinson's Disease and Parkinsonism

Layout table for study information
Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Official Title: LIPAD - LRRK2 International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Actual Study Start Date : January 20, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Group/Cohort
PD + LRRK2
Patients with LRRK2-associated Parkinson's syndrome
no PD + LRRK2
Participants with LRRK2-mutations but without Parkinson's symptoms
no PD + no LRRK2
Participants without mutations and without Parkinson's symptoms
PD+ other than LRRK2
Parkinson patients with mutations in other genes than LRRK2
PD+ no LRRK2
Patients with idiopathic Parkinson's disease



Primary Outcome Measures :
  1. Epidemiology of LRRK2-positive patients [ Time Frame: 2 years ]
    Description of the frequency of all important clinical signs and symptoms including non-motor signs and factoring in the most important influencing factors such as sex, disease duration, and medication. We will report raw and corrected frequencies with 95% confidence intervals.


Secondary Outcome Measures :
  1. Analysis of penetrance of LRRK2 mutations [ Time Frame: 2 years ]
    Penetrance rates (the proportion of individuals with LRRL2 mutation who exhibit clinical symptoms of Parkinson's disease) and phenotypes, and will try to predict penetrance in logistic regression models and quantify the influence of different factors impacting on penetrance.

  2. Analysis of expressivity of LRRK2 mutations [ Time Frame: 2 years ]
    We will analyze expressivity (the degree in which a genotype is phenotypically expressed) of LRRK2 mutations. We will first define meaningful categories using our phenotypic data and then proceed to identify influencing factors.


Biospecimen Retention:   Samples With DNA

Blood and urine samples will be biochemically analysed to determine factors leading to incomplete penetrance in LRRK2 positive carriers and biomarkers of Parkinson's disease.

In blood samples DNA and DNA methylation, RNA and proteins will be analysed. Urine samples will be analysed using NGS-based sequencing of the mitochondrial genome and search for mitochondrial DNA deletions.

Dust will be analysed toxicologically.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Patients with Parkinson's disease or family members of participants with LRRK2 parkinsonism or members of a high risk population with an early PD onset, able to provide informed consent and equal or older than 18 years old.
Criteria

Inclusion Criteria:

  • Informed consent is obtained from the participant.
  • The participant is clinically diagnosed with Parkinson's disease or the individual is a family member of a participant with LRRK2 parkinsonism or is a member of a high risk population with an early PD onset.
  • The participant is equal to or older than 18 years old.

Exclusion Criteria:

  • Inability to provide informed consent.
  • The participant is not suffering from Parkinson's disease or the individual is not a family member of a participant with LRRK2 parkinsonism or is not a member of a high risk population.
  • The participant is younger than 18 years old.
  • Previously enrolled in the study.
  • Participant in custody.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04214509


Contacts
Layout table for location contacts
Contact: Meike Kasten, Prof. Dr. +4945131017518 lipad.ropad@neuro.uni-luebeck.de

Locations
Layout table for location information
Germany
Institute of Neurogenetics Recruiting
Luebeck, Schelswig-Holstein, Germany, 23562
Contact: Tatiana Usnich, MD, PhD    +4945131017518      
Contact: Nathalie Schell, MD    +4945131017518      
Sponsors and Collaborators
University of Luebeck
CENTOGENE GmbH Rostock
Investigators
Layout table for investigator information
Principal Investigator: Christine Klein, Prof. Dr. Institute of Neurogenetics, University of Luebeck
Principal Investigator: Meike Kasten, Prof. Dr. Department of Psychiatry, University of Luebeck
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Meike Kasten, Prof., University of Luebeck
ClinicalTrials.gov Identifier: NCT04214509    
Other Study ID Numbers: LIPAD
First Posted: January 2, 2020    Key Record Dates
Last Update Posted: February 27, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The Plan will be defined at later stages.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Meike Kasten, University of Luebeck:
genetic Parkinson's disease
LRRK2
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases